{"id":"dbfb98ef-bac9-5ab5-beff-46655410da79","stable_key":"e3f6ce02-0bd7-5103-acc1-68503ab6751b:ad00-null","predicate":"no_detected_change_in_recorded_comparison","statement":"The prospective early-onset Alzheimer trial also found no primary intention-to-treat benefit of ALCAR.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"f483149a-f267-52d3-b113-f50bc92401c9","mechanism_event_label":"The prospective early-onset Alzheimer trial also found no primary intention-to-treat benefit of ALCAR.","subject":{"id":"5ce394a9-6ec6-56dd-866f-37d85c0556e4","slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"},"object":{"id":"4ba056b1-f961-57b4-88b4-129dec760232","slug":"human-ad-cognitive-decline","display_name":"Human Alzheimer trial cognitive and functional decline","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"f483149a-f267-52d3-b113-f50bc92401c9","stable_key":"e3f6ce02-0bd7-5103-acc1-68503ab6751b:ad00-null-event","event_type":"experimental_observation","label":"The prospective early-onset Alzheimer trial also found no primary intention-to-treat benefit of ALCAR.","description":"### ad00-null\n\nThe prospective early-onset Alzheimer trial also found no primary intention-to-treat benefit of ALCAR.\nA completer-only MMSE signal did not overturn null primary ADAS-cognitive and CDR results.\nModel and exposure: 229 randomized, ages 45–65; ALCAR 1 g three times daily versus placebo for one year.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. | 2000 | https://pubmed.ncbi.nlm.nih.gov/10994000/ | https://doi.org/10.1212/wnl.55.6.805 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"5ce394a9-6ec6-56dd-866f-37d85c0556e4","slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"ALCAR 3 g/day for one year","sequence_order":0,"notes":""},{"entity":{"id":"4ba056b1-f961-57b4-88b4-129dec760232","slug":"human-ad-cognitive-decline","display_name":"Human Alzheimer trial cognitive and functional decline","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"no_detected_change","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"ALCAR 3 g/day for one year\", \"comparator\": \"Placebo\", \"endpoint\": \"The prospective early-onset Alzheimer trial also found no primary intention-to-treat benefit of ALCAR.\", \"effect_direction\": \"no_detected_change\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; source-derived draft.","entity":null},{"dimension":"experimental_model","value_text":"229 randomized, ages 45–65; ALCAR 1 g three times daily versus placebo for one year.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived curation with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"The prospective early-onset Alzheimer trial also found no primary intention-to-treat benefit of ALCAR.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. | https://pubmed.ncbi.nlm.nih.gov/10994000/ | https://doi.org/10.1212/wnl.55.6.805","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference ad00-null; A completer-only MMSE signal did not overturn null primary ADAS-cognitive and CDR results.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"70511243-d60b-531a-9f32-39f7d8fb6e55","evidence_kind":"source_excerpt","locator":"Lines 603-609","start_line":603,"end_line":609,"excerpt":"### ad00-null\n\nThe prospective early-onset Alzheimer trial also found no primary intention-to-treat benefit of ALCAR.\nA completer-only MMSE signal did not overturn null primary ADAS-cognitive and CDR results.\nModel and exposure: 229 randomized, ages 45–65; ALCAR 1 g three times daily versus placebo for one year.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. | 2000 | https://pubmed.ncbi.nlm.nih.gov/10994000/ | https://doi.org/10.1212/wnl.55.6.805 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","model_system":"229 randomized, ages 45–65; ALCAR 1 g three times daily versus placebo for one year.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"2588f904-245a-597a-8a12-65118013fb90","stable_key":"import-e3f6ce02-0bd7-5103-acc1-68503ab6751b","title":"Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed.","file_path":"","sha256":"84cc82d6fbb0fd5d73c4ce779e9f88e7f0184ba2d29b18ad0f153815380f2975","revision_id":"dac7a950-dbe5-5c7a-9c70-2ea711d5c71a","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}